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We assessed the effect of co-infection by hepatitis C virus (HCV) on immunological and virological response at 48 weeks from
initiation of antiretroviral therapy (ART).
We included patients from the Cohort of Spanish HIV Research Network (CoRIS) starting ART between January 2004 and
November 2014, had at least 1 CD4 T-cell count and viral load measurements both in the previous 6 months and at 48 (±12) weeks
from ART initiation, and HCV serology before ART initiation. We used linear regression for mean differences in CD4 T-cell count
increase from ART initiation and logistic regression to estimate odds ratios for virological response.
Of 12,239 patients by November 30, 2015, 5070 met inclusion criteria: 4382 (86.4%) HIV mono-infected and 688 (13.6%) HIV/
HCV co-infected. Co-infected patients were more likely to have acquired HIV through injecting drugs use (57.4% vs. 1.1%), to be
women, older, and Spanish, have a lower educational level, and having started ART with lower CD4 counts and acquired
immunodeficiency syndrome. CD4 T-cell count increase at 48 weeks was 229.7cell/mL in HIV-monoinfected and 161.9cell/mL in
HIV/HCV-coinfected patients. The percentages of patients achieving a virological response at 48 weeks were 87.0% and 78.3% in
mono and coinfected patients, respectively. Multivariable analyses showed that at 48 weeks, coinfected patients increased 44.5
(95% confidence interval [CI]: 24.8–64.3) cells/mL less than monoinfected and had lower probability of virological response (odds
ratio: 0.62; 95% CI: 0.44–0.88).
HIV/HCV-coinfected patients have lower immunological and virological responses at 48 weeks from ART initiation than
monoinfected patients.
Abbreviations: x2 = chi-squared test, mL = microliter, AIDS = acquired immunodeficiency syndrome, ART = antiretroviral
therapy, CI = confidence interval, CIBERESP = Centro de Investigación Biomédica en Red en Epidemiología y Salud Publica, CoRIS
=Cohort of Spanish HIV Research Network, DAA’s= direct-acting antivirals, HBsAg= hepatitis B surface antigen, HCV=Hepatitis C
Virus, HIV=Human Immunodeficiency Virus, IDU= Injecting Drugs Users, IQR= Interquartile Range, mL=milliliter, MSM=menwho
have sex with men, OR = odds ratio, RNA = ribonucleic acid, STR = single-tablet regimens.
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Coinfection with hepatitis C virus (HCV) and human immuno-
deficiency virus (HIV) has been associated with a faster
progression of hepatitis and higher liver-related mortality.[1–3]
However, the effect of co-infection on HIV progression and
responses to HIV antiretroviral therapy (ART) seems less clear.
Various studies have reported poorer immunological response to
ART in HIV/HCV co-infected patients,[4–11] whereas others have
not found significant differences.[12–15] Regarding the virological
response to ART, most studies have not found significant
differences, [7,8,12,16] although Hua et al[9] reported a worse
response in co-infected patients. It could be argued that
inconsistent results might be explained by the heterogeneity of
the populations in the different studies, the different study periods
reflecting diverse ART regimens and small sample sizes.[9,16]
However, there are well-described biological mechanisms that
could explain the different responses observed between coin-
fected and monoinfected individuals.[1,17–19]
The estimated global prevalence of HCV coinfection in HIV-
positive individuals in 2013 was between 9.2% and 37.3%,[20]
and Spain was situated on the top of the rank in 2015.[21] This
very high prevalence of HCV coinfection in HIV-positive
persons in Spain reflects a unique HIV epidemiological pattern
pertaining the elevated numbers of persons who became
infected through illicit drug use in the 1980s and 1990s which
has declined over time, and with it, the proportion of co-
infected subjects.[22]
Given the inconsistencies previously highlighted in the
literature, the major changes in HIV clinical management in
recent years and the lack of contemporary data addressing this
question in Spain, we aimed to assess the effect of coinfection
by HCV on immunological and virological response at 48Figure 1. Flowchart of t
2
weeks from ART initiation in HIV-positive patients in the
Cohort of the Spanish HIV Research Network (CoRIS) from
January 2004 till November 2015. Additionally, we also
modeled immunological responses in patients with optimal
HIV responses to ART.2. Methods
2.1. Study design, setting and participants
The Cohort of the Spanish HIV Research Network (CoRIS) is an
open, multicenter, prospective cohort of HIV-infected individuals
older than 13 years, naïve to ART at study entry, seen for the first
time from 1 January 2004 at any of the 42 centers in 13 of the 17
autonomous regions in Spain. Subjects agree to participate in the
study by signing an informed consent form. Ethics approval was
obtained from all hospitals Ethic’s Committees and every patient
provides written informed consent to participate. CoRIS collects a
minimum data set as described in the cohort protocol, which
includes baseline and follow-up sociodemographic, immunological,
and clinical data. Data are subjected to internal quality controls.
Patients are followed periodically under routine clinical practice.[23]
Patients considered for inclusion were baseline ART naïve
patients, aged ≥18 years, who started ART between 1 January
2004 and 30November 2014 and had a CD4 T-cell count and an
HIV viral loadmeasurement both in the previous 6months and at
48 (±12) weeks fromART initiation, andHCV serology previous
to ART initiation. Because direct-acting antivirals (DAAs) were
not widely available in Spain at the time of these analyses, none of
the patients included had received them. Information regarding
HCV treatment with interferon and ribavirin was not collected at
the time and was, therefore, not taken into account in the
analysis. A detailed flow chart is shown in Figure 1.he study population.
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CoRIS collects information about birthdate, sex (male, female),
geographical origin, education level (high school or lower,
secondary, university, unknown), age, and year at start of ART,
HIV-transmission category (men who have sex with men [MSM],
injecting drugs users [IDU], heterosexual, unknown), CD4 T-cell
count, HIV viral load, acquired immunodeficiency syndrome
(AIDS) progression, hepatitis B surface antigen, hepatitis C
antibodies, follow-up center, initial ART regimen, among others.
Subjects were classified at baseline as HIV-monoinfected and
HIV/HCV-coinfected based on HCV serological findings.Table 1





N 4382 (86.4) 688 (13.6)
Sex, N (%) <.001
Male 3662 (83.6) 517 (75.2)
Female 720 (16.4) 171 (24.9)
Age at start of ART, y, N (%)
Median (IQR) 36.4 (30.5–43.7) 41.8 (36.7–46.4) <.001
<50 3821 (87.2) 597 (86.8) .76
≥50 561 (12.8) 91 (13.2)
HIV transmission category, N (%) <.001
MSM 2743 (62.6) 95 (13.8)
IDU 46 (1.1) 395 (57.4)
Heterosexual 1454 (33.2) 177 (25.7)
Unknown 139 (3.2) 21 (3.1)
Education level, N (%) <.001
High school or lower 1405 (32.1) 392 (57.0)
Secondary 1238 (28.3) 142 (20.7)
University 1100 (25.1) 42 (6.1)
Unknown 639 (14.6) 112 (16.3)
Origin, N (%) <.001
Spain 2974 (67.9) 582 (84.6)
Not Spain 1408 (32.1) 106 (15.4)
CD4 count pre-ART, cell/mL, N (%)
Median (IQR) 288 (166–401) 220 (96–342) <.001
<200 1377 (31.4) 299 (43.5) <.001
200–350 1502 (34.3) 223 (32.4)
>350 1503 (34.3) 166 (24.1)
HIV-VL pre-ART, copies/mL, N (%)





<10000 671 (15.3) 132 (19.2) .03
10000–100000 1947 (44.4) 286 (41.6)
>100000 1764 (40.3) 270 (39.2)
AIDS pre-ART, N (%) <.001
Negative 3784 (84.4) 529 (76.9)
Positive 598 (13.7) 159 (23.1)
HBsAg pre-ART, N (%) .42
Negative 3795 (86.6) 585 (85.0)
Positive 169 (3.9) 33 (4.8)
Unknown 418 (9.5) 70 (10.2)
Initial ART regimen, N (%)
2 NRTI+1 NNRTI 2553 (58.3) 310 (45.1) <.001
2 NRTI+1 PI 809 (18.5) 158 (23.0)
NRTI+1 II 879 (20.1) 194 (28.2)
Other 89 (2.0) 21 (3.1)
Nonspecified 52 (1.2) 5 (0.7)
Year at start of ART, N (%)
Median (IQR) 2010 (2008–2012) 2008 (2006–2011) <.001
2004–2007 1043 (23.8) 278 (40.4) <.001
2008–2014 3339 (76.2) 410 (59.6)
ART= antiretroviral therapy, AIDS=acquired immunodeficiency syndrome, HBsAg=hepatitis B
surface antigen, HCV=hepatitis C virus, HIV=human immunodeficiency virus, HIV-VL=HIV viral
load, IDU= injection drug use, II= integrase inhibitor, IQR= interquartile range, mL=milliliter, MSM=
men who have sex with men, N=number, NNRTI=non-nucleoside reverse transcriptase inhibitor,
NRTI=nucleoside reverse transcriptase inhibitor, PI=protease inhibitor, mL=microliter.2.3. Outcomes
Immunological response was defined as the change in CD4 T-cell
counts at week 48 (±12) from ART initiation, and virological
response as achieving a viral load 50 HIV-1 ribonucleic acid
(RNA) copies/milliliter (mL) at 48 (±12) weeks from ART
initiation.
2.4. Statistical analysis
A descriptive analysis of patients’ characteristics was carried out
using frequency tables for categorical variables and median and
interquartile range (IQR) for continuous variables. Differences in
sociodemographic and clinical characteristics between HIV/
HCV-coinfected and HIV-monoinfected patients were assessed
through the nonparametric Mann–Whitney test for continuous
variables and the x2 test for independence for categorical
variables.
Linear regression models were used to estimate the mean
difference in the increase in CD4 T-cell counts at week 48 (± 12)
from ART initiation, comparing HIV/HCV-coinfected versus
HIV-monoinfected patients. Logistic regression models were
used to estimate the odds ratio (OR) for the association between
HIV/HCV coinfection and virological response at week 48 (±12)
from the start of ART.
All themodels were adjusted for potential confounders defined
a priori: sex, age at start ART, HIV transmission category,
geographical origin, educational level (a proxy of socio-
economic status), CD4 T cells count pre-ART, HIV viral load
pre-ART and AIDS pre-ART, hepatitis B infection pre-ART, and
year at start ART. We assessed whether any of the variables
studied modified the effect of HCV co-infection on immunologi-
cal and virological response by including interaction terms in
multivariable models.
We considered a possible interaction for period effect, in
relation with 2 major changes on ART by 2008: extended use of
single-tablet regimens (STR) that improves adherence and viral
suppression[24] and widespread introduction of integrase inhib-
itors.[25] Because of that, we performed a sensitivity analyses,
looking for the outcomes variables in both periods 2004 to 2007
and 2008 to 2015.
We considered the possibility of poor adherence in relation to
no viral suppression, proposed in other studies, and modeled
immunological responses in patients with optimal virological
responses.
To adjust for clustering of patients within centres, robust
methods were used to estimate standard errors and, thus, to
calculate 95% confidence intervals (CI) and P values. Wald tests
were used to derive P values. All statistical analyses were




CoRIS database, updated at 30 November 2015, included 12,239
individuals of whom 5070 met the inclusion criteria (Fig. 1), 4382
(86.4%) were HIV-monoinfected and 688 (13.6%) were HIV/
HCV-coinfected patients. HIV/HCV-coinfected patients were
more likely than those HIV-monoinfected to have acquired HIV
through injectingdrugsuse, tobewomen, older at the start ofART,
of Spanish originwith lower education level, and startedARTwith
a lower CD4 count and an AIDS diagnosis (Table 1).3.2. Change in CD4 T-cell counts at week 48 from ART
initiation
Mean (95% CI) CD4 T-cell increase at week 48 from ART
initiation was 229.7 (224.2–235.2) cells/mL in HIV-monoinfected
Table 2
Impact of coinfection by HCV on immunological Response at 48 weeks from ART initiation.
Univariable analyses Multivariable analyses
∗
n
Mean of increase in
CD4 T-cell count, cells/mL, CI 95%
Difference in mean CD4 T-cell
count increase, cells/mL, 95% CI P
Difference in mean CD4 T-cell
count increase, cells/mL, 95% CI P
HCV () 4382 229.7 (224.2–235.2) 0 0
HCV (+) 688 161.9 (149.7–174.2) 67.8 (87.4 to 48.1) <.001 44.5 (64.3 to 24.8) <.001
∗
Adjusted for HIV transmission category.
ART=antiretroviral therapy, CI= confidence interval, HCV=hepatitis C virus, mL=microliter.
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coinfected patients (P< .001). In univariable analyses, the
difference in mean CD4 T-cell count increase between HIV/
HCV-coinfected and HIV-monoinfected patients was 67.8 (95%
CI: 48.1–87.4) cells/mL. After adjustment for HIV transmission
category, which appeared to be the only variable that confounded
the association of interest, the difference inmeanCD4 T-cell count
increase was reduced to 44.5cell//mL (95% CI: 24.8–64.3) but
remained statistically significant (P< .001) (Table 2). We failed to
find any evidence suggesting that any of the variables studied
modified the effect of HCV-coinfection on the immunological
response to ART, including a possible period effect (all interaction
P values ≥.05).
We modeled immunological responses in patients with optimal
virological responses, and we found that the difference in mean
CD4 T-cell count increase was reduced to 37.1cell//mL (95% CI:
15.1–59.2) but remained statistically significant (P= .002).3.3. Virological response at 48 weeks after ART initiation
At 48 weeks from ART initiation, 87.0% of HIV-monoinfected
patients and 78.3% of HIV/HCV-coinfected patients achieved
virological response (P< .001). As for immunological response,
HIV transmission category was the only variable that confound-
ed the association of interest and after adjustment for this
characteristic in a multivariable logistic regression model, HIV/
HCV-coinfected patients still had a lower chance of achieving
virological response than HIV-coinfected patients (adjusted OR
0.62; 95% CI 0.44–0.88; P< .01) (Table 3).
There was no evidence suggesting that any of the variables
studied modified the effect of HCV-coinfection on immunologi-
cal response, including a possible period effect (all interaction P
values ≥.05).4. Discussion
We found that HIV/HCV-coinfected patients within a national
and representative cohort in Spain had poorer immunological
and virological responses at 48 weeks from ART initiation thanTable 3
Impact of Co-infection by HCV on Virological Response at 48 weeks
n




HCV () 4382 3811 (87.0)
HCV (+) 688 539 (78.3) 0.54
∗
Adjusted for HIV transmission category.
ART=antiretroviral therapy, CI= confidence interval, HCV=hepatitis C virus, OR= odds ratio.
4
monoinfected patients. We observed these findings in crude and
adjusted analyses, and saw no differential effect of HCV
coinfection on HIV immunological and virological responses
to ART from 2004 until 2015, before the widespread introduc-
tion of DAA’s for the treatment of HCV infection in Spain.[26]
Consequently, we could not see its effects in this analysis.
Our results are consistent with the poorer immunological
response at 48 weeks from ART initiation in HIV/HCV-
coinfected compared to monoinfected patients reported in many
studies, [7,8,10,11,16,27] although not in others.[12] Of note, our
results provide contemporary data supporting the inferior
virological response in coinfected patients compared to mono-
infected patients described byHua et al[9] 15 years ago. It must be
mentioned, however, that most studies have not found statisti-
cally significant differences in virological responses to ART by
HCV infection status[7,8,10,12,16,27]
Many possible reasons explaining the worse responses to ART
of HIV/HCV-coinfected individuals have been proposed. Social
factors, which differentially affect people dually infected with
HIV and HCV, have been suggested as potential confounders or
mediators. Additionally, biological factors connected to HCV
pathogenicity are to be taken into account.
The social and behavioral factors associated with HCV
infection, which could contribute to explain the worse responses
to ART observed in our study include various forms of drug
dependency,[16,27] higher-risk sexual behavior,[3] barriers to
accessing health care,[28] and poorer linkage and retention in
care.[29–33] In the present study, we have adjusted by HIV
transmission category, the main behavioral factor, which
accounted for the differences between groups, other social
factors such as geographical origin and education level. Indeed, as
far as we are aware, no previous study addressing this question
has adjusted for this proxy of socioeconomic level. All other
possible confounders have been evaluated like AIDS state,
Hepatitis B co-infection, and the possibility of a period effect in
relation to changes in ART (widespread introduction of STR and
integrase inhibitors). Additionally, initial treatment regimen has
been assessed, as it can affect the response (schedules that
includes integrase inhibitors can achieve virological responsefrom ART initiation.
Univariable analyses Multivariable analyses
∗
virological
se (95% CI) P
OR of virological
response (95% CI) P
1 1
(0.44–0.66) <.001 0.62 (0.44–0.88) <.01
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between groups. Also, sensitivity analyses have been carried
out, comparing immunological response between groups, only in
the individuals with optimal virological responses, and the
differences between groups remained. Also, Cescon et al[34]
compared the immunological and virological responses between
HIV/HCV-coinfected IDU and HIV/HCV-coinfected non-IDU
individuals, finding no differences in virological response and just
a marginal difference in immunological response. This can
support a direct biological effect of HCV on the responses.
Among the biological factors explaining the effect of HCV on
ART responses, it has been found that in HIV/HCV co-infected
patients, immune activation of memory CD4 T-cells is consider-
ably increased,[19] so is longer immune activation associated with
high CD38 expression in T-cells, regardless of receiving ART.[18]
It has been described that HCV viral proteins can act as ligands
for cell receptors of the immune system, among other cells, like
HCV E2 protein can bind to the CD81 receptor and infect T-cells,
B-cells, and monocytes.[1,27] HCV core significantly seems to
enhance HIV replication in human macrophages by upregulating
Tumoral Necrosis Factor and interleukin-6.[17] These mecha-
nisms could explain the different evolution of the HIV infection in
HIV/HCV-coinfected individuals.
As a limitation of the present study, information on HCV viral
loads was not available for most patients, so we used HCV
serology before ART initiation to classify them as mono or
coinfected. In consequence, patients who spontaneously cleared
HCV infection could have been wrongly classified as HIV/HCV
coinfected patients. However, we do not think this might have
biased our study as spontaneous clearance is believed to be
around 10%—even lower among HIV/HCV co-infected
patients[35]—and in any case, this misclassification bias goes
toward the null hypothesis.
As strengths, this cohort includes patients from all over Spain
with a broad spectrum of patient characteristics and antiretrovi-
ral regimens and is representative of the contemporary HIV
epidemic. The overall number of patients was very high, limiting
the random error found in other studies with smaller sample sizes.
Similarly, this cohort was submitted to strict quality controls,
limiting misclassification errors related to the collection of
information. ART in the patients from the cohort is adjusted to
national HIV treatment guidelines.[23]
The findings of this study have implications for clinical practice
and public health. It is evident that HCV itself has a negative
effect on the response to ART in HIV/HCV co-infected patients.
Knowing that HCV infection has an effective treatment, boosting
access to this treatment has an impact on HCV infection, but also
has an impact on HIV infection and epidemic. As future work,
repeating these analyses in the same cohort when HIV/HCV-
coinfected patients have been treated for HCV may serve to
strengthen the evidence of the need for HCV treatment, mainly as
a public health approach in low-income countries where these 2
infections have a significant effect and/or where effective HCV
treatment is not available.Acknowledgments
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Hospital Universitario Virgen del Rocío (Sevilla): Pompeyo
Viciana, Nuria Espinosa, Luis Fernando López-Cortés.
Hospital Universitario de Bellvitge (Hospitalet de Llobregat):
Daniel Podzamczer, Elena Ferrer, Arkaitz Imaz, Juan Tiraboschi,
Ana Silva, Maria Saumoy.
Hospital Universitario Valle de Hebrón (Barcelona): Esteban
Ribera.
Hospital Costa del Sol (Marbella): Julián Olalla, Alfonso del
Arco, Javier de la torre, José Luis Prada, José María García de
Lomas Guerrero.
Hospital General Universitario Santa Lucía (Cartagena):
Onofre Juan Martínez, Francisco Jesus Vera, Lorena Martínez,
Josefina García, Begoña Alcaraz, Amaya Jimeno.
Complejo Hospitalario Universitario a Coruña (Chuac) (A
Coruña): Eva Poveda, Berta Pernas, Álvaro Mena, Marta
Grandal, Ángeles Castro, José D. Pedreira.
Hospital Universitario Basurto (Bilbao): Josefa Muñoz, Miren
Zuriñe Zubero, Josu Mirena Baraia-Etxaburu, Sofía Ibarra,
Oscar Ferrero, Josefina López deMunain, MMar Cámara. Iñigo
López, Mireia de la Peña.
Hospital Universitario Virgen de la Arrixaca (El Palmar):
Carlos Galera, Helena Albendin, Aurora Pérez, Asunción Iborra,
Antonio Moreno, Maria Ángeles Campillo, Asunción Vidal.
Hospital de laMarina Baixa (La Vila Joiosa): Concha Amador,
Francisco Pasquau, Javier Ena, Concha Benito, Vicenta Fenoll.6
Hospital Universitario Infanta Sofia (San Sebastian de los
Reyes): Inés Suárez-García, Eduardo Malmierca, Patricia
González-Ruano, Dolores Martín Rodrigo.
Complejo Hospitalario de Jaén (Jaen): Mohamed Omar
Mohamed-Balghata, Maria Amparo Gómez Vidal.
Hospital San Agustín (Avilés): Miguel Alberto de Zarraga.
Hospital Clínico San Carlos (Madrid): Vicente Estrada Pérez,
Maria Jesus Téllez Molina, Jorge Vergas García, Elisa Pérez-
Cecila Carrera.
Hospital Universitario Fundación Jiménez Díaz (Madrid):
Miguel Górgolas., Alfonso Cabello., Beatriz Álvarez., Laura
Prieto.
Hospital Universitario Príncipe de Asturias (Alcalá de
Henares): Jose Sanz Moreno, Alberto Arranz Caso, Julio de
Miguel Prieto, Esperanza Casas García.
Hospital Universitario Fundación Alcorcón (Alcorcón): Juan
Emilio Losa, Maria Velasco Arribas, Leonor Moreno Nuñez,
Rafael Hervás Gómez.
Hospital Clínico Universitario de Valencia (València): Maria
Jose Galindo Puerto, Ramón Fernando Vilalta, Ana Ferrer
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